Tirzepatide vs Semaglutide: 4.3 Percentage Points More Weight Loss, Higher Serious Adverse Event Rate, Across 10 Head-to-Head Studies of 41,381 Adults

The largest head-to-head synthesis of tirzepatide versus semaglutide as of September 2026 pulled 10 studies together: three randomized controlled trials (including SURMOUNT-5, published in the New England Journal of Medicine in 2025) and seven retrospective cohort studies drawn from electronic health records and pharmacy claims. Total pooled population: 41,381 adults with overweight or obesity, most without type 2 diabetes.

The efficacy result is straightforward. Across 10 studies, tirzepatide produced a mean 4.28 percentage points more weight loss than semaglutide as a percent of baseline body weight. Across 8 studies with absolute weight-loss data, tirzepatide produced about 4.43 kg (9.7 lbs) more absolute weight loss. In the one direct comparison people usually cite — SURMOUNT-5 in adults with obesity but no diabetes over 72 weeks — Zepbound produced 20.2% weight loss versus Wegovy's 13.7%, a 6.5-percentage-point gap.

On safety, the picture is more nuanced. Gastrointestinal side effects (nausea, vomiting, constipation, diarrhea) were common in both arms and slightly more common with tirzepatide. Serious adverse events — the category that includes hospitalization, life-threatening reactions, and events requiring drug discontinuation — were rare in both arms but showed up somewhat more often on tirzepatide.

The practical question for most patients and prescribers is not which drug loses more weight in a trial. It is which drug your insurance covers, at what copay, and whether the safety trade-off matters for your specific situation. This piece covers what the pooled data show, where the numbers translate into meaningful clinical differences, and where cost and coverage usually end up making the choice.

Head-to-head clinical comparisons of two drugs are rare because they are expensive to run and one manufacturer usually has more to lose than to gain. Getting to 10 studies took several years of pharmaceutical company investment (SURMOUNT-5 was Lilly-funded and designed to show tirzepatide is better than semaglutide) plus academic and insurer-driven work using real-world data.

The three randomized controlled trials in the pool included SURMOUNT-5 (the most-cited direct comparison, 751 adults, 72 weeks, adults with obesity but no diabetes) plus two smaller trials in adults with obesity plus type 2 diabetes. Randomized comparisons are the gold standard because random assignment balances known and unknown patient characteristics between treatment groups.

The seven retrospective cohort studies pulled from electronic health records and pharmacy claims databases. These studies have much larger populations but no random assignment. Statistical adjustment (propensity score matching, multivariable regression) tries to compare similar patients, but hidden differences between people who end up on tirzepatide versus semaglutide can bias the results in either direction. Real-world studies also usually have shorter follow-up than trials, so weight-loss numbers may be smaller than the trial data would predict.

Meta-analysis combines the effect estimates from all 10 studies, weighted by their size and precision. The pooled 4.28-percentage-point gap is a weighted average across the different study designs, follow-up periods, and patient populations. That is why the SURMOUNT-5 direct number (6.5 points) is larger — SURMOUNT-5 had the longest follow-up and a clean adult-obesity population, which is where tirzepatide seems to work best.

A 4.28-percentage-point difference in mean weight loss sounds small until you translate it. For an adult starting at 220 lbs (100 kg), that gap is 9.4 lbs (4.3 kg). At 300 lbs (136 kg), it is 12.8 lbs (5.8 kg). Over a year on either drug, that difference can push a patient from the overweight range down into a healthier BMI category, or from obesity class I into overweight.

What the pooled data show is that tirzepatide, on average, produces more weight loss than semaglutide across most patient groups. That is consistent with tirzepatide's dual mechanism (both GLP-1 and GIP receptor activation) versus semaglutide's single GLP-1 mechanism. The GIP piece of tirzepatide seems to add appetite suppression and metabolic benefits on top of what the GLP-1 piece contributes.

What the pooled data do not show is that tirzepatide is universally better. Real-world data shows that a subset of patients respond better to semaglutide than to tirzepatide. Some patients tolerate one drug and not the other. Some patients hit their weight-loss target on either drug and stop before the ceiling difference becomes visible. And the SURMOUNT-5 population (adults with obesity, no diabetes) may not generalize to older patients, patients with kidney disease, or patients with a long list of concurrent medications where drug interactions matter more.

One finding that gets less attention: both drugs also reduce cardiovascular events and improve blood-sugar control in patients with type 2 diabetes. The SELECT trial for semaglutide showed a 20% reduction in major cardiovascular events in adults with obesity without diabetes but with established cardiovascular disease. Similar cardiovascular outcome trials for tirzepatide are running and have not yet reported at the same level of maturity.

Gastrointestinal side effects lead the safety comparison. Nausea shows up in about 30-45% of patients on either drug during dose titration; vomiting in 10-20%; constipation and diarrhea in 15-25%. The tirzepatide rates run slightly higher across most of these categories, particularly during the first several weeks after each dose increase. Most patients tolerate the drugs well enough to stay on treatment; discontinuation rates for gastrointestinal side effects are typically 4-7% in trials.

Serious adverse events are rare on either drug. The pooled data flag a somewhat higher rate on tirzepatide, though the absolute numbers are small (single-digit percentages in most studies) and the categories included are heterogeneous. Cases of pancreatitis, gallbladder disease requiring surgery, and severe dehydration have been reported with both drugs. Tirzepatide's higher gastrointestinal burden may drive some of the excess serious adverse events — severe vomiting can cause dehydration and electrolyte problems that then require hospitalization.

Specific safety topics that come up in patient conversations:

Pancreatitis. Both drugs carry a warning about acute pancreatitis. Absolute risk is very low in patients without risk factors, but any patient with prior pancreatitis or symptomatic gallstones should discuss risk explicitly with their prescriber before starting.

Gallbladder disease. Rapid weight loss on either drug can trigger gallstone formation and gallbladder attacks. Patients with pre-existing gallbladder disease may face higher risk.

Thyroid C-cell tumors. Both drugs carry a boxed warning about medullary thyroid cancer based on rodent studies. Human cases have not been established, but patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not take either drug.

Suicidal ideation. The FDA reviewed reports of new-onset or worsened suicidal thoughts on GLP-1 drugs in 2024-2025 and did not find a causal link. Ongoing surveillance continues. Patients with active mental health concerns should discuss with their prescriber.

Muscle loss during weight loss. Both drugs contribute to muscle loss along with fat loss during rapid weight reduction, which is common to any large weight-loss intervention. Resistance training and adequate protein intake help preserve muscle.

SURMOUNT-5 published in the New England Journal of Medicine in 2025 remains the most-cited direct comparison because it is the longest and cleanest randomized head-to-head between tirzepatide and semaglutide. Lilly funded and designed it. The trial enrolled 751 adults with obesity but without type 2 diabetes, randomized them to Zepbound (up to 15 mg weekly) or Wegovy (up to 2.4 mg weekly), and followed them for 72 weeks.

At 72 weeks, mean weight loss was 20.2% on Zepbound versus 13.7% on Wegovy, a 6.5-percentage-point difference. The proportion of participants losing 15% or more of body weight was 65.1% on Zepbound versus 39.6% on Wegovy. Both differences were statistically significant with narrow confidence intervals.

Side effects were common in both arms but not enormously different: gastrointestinal effects were the most common, occurring in about two-thirds of participants on either drug at some point during titration, and dropping to lower rates once patients reached a stable dose. Discontinuation for adverse events was 6.1% on Zepbound and 8.0% on Wegovy — a small edge for tirzepatide here, despite slightly higher gastrointestinal burden in some earlier trials.

The main limitation of SURMOUNT-5 is generalizability. It enrolled adults without diabetes, mostly aged 40-60, mostly female, mostly White or Hispanic, and mostly with body mass index 30-40. Patients outside this range — older adults with multiple conditions, patients with severe obesity class III, patients on many other medications — may respond differently on both efficacy and safety. Real-world data suggests the tirzepatide edge holds across broader populations but with somewhat smaller effect sizes than the trial.

For most patients, the efficacy gap between tirzepatide and semaglutide matters less than what their insurance will pay for.

Both drugs' list prices (wholesale acquisition cost, or WAC — the sticker price manufacturers publish before rebates and discounts) run north of $1,000 per 28-day supply: Zepbound at $1,059 and Wegovy at $1,349 in the U.S. as of mid-2026. But list prices are rarely what patients or insurers end up paying. Rebates negotiated between pharmacy benefit managers (PBMs — the middlemen who administer prescription drug benefits for insurers and employers) and manufacturers reduce the net cost, and manufacturer coupons further reduce the copay for commercially insured patients.

What patients see at the pharmacy counter depends on the plan:

Commercial insurance with GLP-1 obesity coverage. Copays typically run $25-$100 per month with manufacturer coupons. Plans usually cover one drug preferentially through their formulary — commonly the drug whose manufacturer offered the deepest rebate — and cover the other drug at a higher copay or with additional prior authorization steps. Ask your pharmacist to run both drugs through your insurance before committing.

Medicare beneficiaries with type 2 diabetes. Ozempic (semaglutide) and Mounjaro (tirzepatide) have long been covered under Medicare Part D for diabetes. Copays vary by plan. The November 2025 pricing agreement between the Trump administration, Lilly, and Novo Nordisk drops the Medicare price to $245 per month with a $50 copay.

Medicare beneficiaries with obesity plus a qualifying comorbidity. The same November 2025 agreement created a new coverage pathway for Wegovy and Zepbound at obesity indications. Coverage kicks in as CMS finalizes formulary guidance through 2026.

Uninsured or cash-pay patients. Cash-pay direct-to-consumer programs run about $499 per month for Wegovy through NovoCare and about the same for Zepbound through LillyDirect. TrumpRx launched February 2026 at $350 per month for injectable starting doses, trending toward $245.

The practical implication: if your insurance clearly prefers one drug over the other, take the preferred one and save your energy for other decisions. The tirzepatide-versus-semaglutide efficacy gap matters most when you have real choice.

For most patients starting a GLP-1 for the first time, the efficacy edge favors tirzepatide and the safety trade-off is small enough to ignore. Some situations warrant a closer look.

A prior history of severe gastrointestinal issues (gastroparesis, chronic nausea, inflammatory bowel disease, or difficulty maintaining hydration) may tilt toward semaglutide because it produces somewhat lower gastrointestinal burden on average. It also tilts toward slower dose titration on either drug.

Prior gallbladder disease or a strong family history of pancreatitis warrants explicit conversation about both drugs' warnings. Neither drug is clearly safer than the other on these specific outcomes, but the shared class-level risk deserves a plan.

Older adults (over 70) with multiple concurrent medications may want the more established safety database of semaglutide (approved for obesity since 2021, longer real-world track record) rather than the newer tirzepatide obesity indication (approved 2023). This is judgment, not clear data.

Patients with type 2 diabetes plus established cardiovascular disease may want semaglutide for the specific SELECT trial evidence of cardiovascular event reduction. Similar tirzepatide data are pending. This is the one clinical situation where semaglutide currently has a specific evidence advantage.

Patients whose insurance covers one drug clearly better than the other should take the covered drug. The efficacy gap between the two is smaller than the practical burden of paying full retail.

And patients who fail to lose meaningful weight on one drug after several months at the maximum tolerated dose can reasonably switch to the other; both directions of switching have shown some patients respond to the second drug after not responding to the first. Discuss the transition plan with your prescriber (both drugs require dose titration on the way in, and stopping one before starting the other reduces overlap concerns).

If you are choosing between tirzepatide and semaglutide, or considering a switch, a useful conversation with your prescriber covers a few specific points.

What does my insurance cover, and at what copay? Ask the pharmacist to run both drugs before you commit. The answer may make the rest of the discussion moot.

What is my starting BMI and weight-loss goal? A patient targeting 5-10% weight loss for a specific health indication (sleep apnea, pre-diabetes reversal, joint pain reduction) may reach their goal on either drug. A patient targeting more aggressive weight loss for a specific health reason (avoiding bariatric surgery, treating fatty liver disease) may benefit more from the tirzepatide efficacy edge.

Do I have any of the specific risk factors that change the safety calculus? Prior pancreatitis, gallbladder disease, medullary thyroid cancer family history, active mental health issues, or severe gastrointestinal problems.

What is the titration plan and what should I do if the first dose is intolerable? Both drugs require gradual dose escalation. Knowing in advance what "call the office" versus "push through" looks like helps avoid unnecessary discontinuation.

How will we know if this is working — and when will we decide whether to switch or add? A written plan (weight-loss target at 3, 6, and 12 months; what would trigger a dose change; what would trigger a switch) helps avoid drift.

Do I need to keep taking this forever? Both drugs work while you take them. Weight regain within a year of stopping is well-documented and averages about two-thirds of lost weight. Long-term treatment is the plan for most patients; that reality shapes what you should be willing to pay per month and what side-effect burden is livable over years.

This piece is educational and reflects publicly available information as of September 13, 2026. It is not medical advice. Talk to the clinician who prescribes for you. Peptide profile background: tirzepatide on Peptidelist.org, semaglutide on Peptidelist.org.